唐氏综合征相关急性淋巴细胞白血病的基因组图谱
该研究对295例唐氏综合征相关急性淋巴细胞白血病(DS-ALL)进行全基因组测序和全转录组测序,并与2257例非DS-ALL比较,识别出15种分子亚型,CRLF2-r、IGH::IGF2BP1和C/EBPalt亚型显著富集,C/EBP激活占10.5%,RAG介导的体细胞基因组异常中位占结构变异的27.5%。
要点
- DS-ALL存在15种分子亚型,CRLF2-r、IGH::IGF2BP1和C/EBPalt较非DS-ALL显著富集。
- 10.5%的DS-ALL通过多种基因组机制激活CEBPD、CEBPA和CEBPE。
- CRLF2重排DS-ALL中BCR::ABL1样亚型与较差的无事件生存相关。
核心结论
- 研究结果提供了DS-ALL生物学的重要见解,并指出靶向治疗和个体化治疗的机会。
研究设计与样本
- 对295例DS-ALL病例进行全基因组测序和全转录组测序(RNA-Seq),并与2257例非DS-ALL病例进行整合基因组分析比较。
- 对CRLF2重排的DS-ALL进行无监督层次聚类分析。
- 在小鼠造血祖细胞中进行体外实验,观察CEBPD过表达对分化为前B细胞的影响。
主要发现
- 整合基因组分析识别出15种DS-ALL分子亚型,CRLF2-r、IGH::IGF2BP1和C/EBPalt亚型较2257例非DS-ALL显著富集。
- 10.5%的DS-ALL病例通过染色体易位和非编码突变导致增强子劫持等多种基因组机制异常激活CEBPD、CEBPA和CEBPE基因。
- 42.3%的C/EBP激活DS-ALL同时伴有FLT3点突变或插入/缺失,而其他亚型中该比例为4.1%。
- CEBPD过表达在体外增强小鼠造血祖细胞向pro-B细胞分化,尤其在DS遗传背景下。
- RAG介导的体细胞基因组异常在DS-ALL中常见,中位占结构变异的27.5%,而非DS-ALL中为7.7%。
关键数值与推荐
- DS-ALL中C/EBP激活(CEBPD、CEBPA、CEBPE异常激活)占10.5%。
- C/EBP激活DS-ALL中42.3%伴FLT3点突变或插入/缺失,其他亚型为4.1%。
- RAG介导的体细胞基因组异常中位占DS-ALL结构变异的27.5%,非DS-ALL为7.7%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Trisomy 21, the genetic cause of Down syndrome (DS), is the most common congenital chromosomal anomaly. It is associated with a 20-fold increased risk of acute lymphoblastic leukemia (ALL) during childhood and results in distinctive leukemia biology. To comprehensively define the genomic landscape of DS-ALL, we performed whole-genome sequencing and whole-transcriptome sequencing (RNA-Seq) on 295 cases. Our integrated genomic analyses identified 15 molecular subtypes of DS-ALL, with marked enrichment of CRLF2-r, IGH::IGF2BP1, and C/EBP altered (C/EBPalt) subtypes compared with 2257 non-DS-ALL cases. We observed abnormal activation of the CEBPD, CEBPA, and CEBPE genes in 10.5% of DS-ALL cases via a variety of genomic mechanisms, including chromosomal rearrangements and noncoding mutations leading to enhancer hijacking. A total of 42.3% of C/EBP-activated DS-ALL also have concomitant FLT3 point mutations or insertions/deletions, compared with 4.1% in other subtypes. CEBPD overexpression enhanced the differentiation of mouse hematopoietic progenitor cells into pro-B cells in vitro, particularly in a DS genetic background. Notably, recombination-activating gene-mediated somatic genomic abnormalities were common in DS-ALL, accounting for a median of 27.5% of structural alterations, compared with 7.7% in non-DS-ALL. Unsupervised hierarchical clustering analyses of CRLF2-rearranged DS-ALL identified substantial heterogeneity within this group, with the BCR::ABL1-like subset linked to an inferior event-free survival, even after adjusting for known clinical risk factors. These results provide important insights into the biology of DS-ALL and point to opportunities for targeted therapy and treatment individualization.
引用
- Li Z, Chang TC, Junco JJ, et al. Genomic landscape of Down syndrome-associated acute lymphoblastic leukemia. Blood. 2023. PMID: 37001051. doi:10.1182/blood.2023019765
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。